Loading…
Loading…
LYRA does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for LYRA and 80,000+ other tickers.
See exactly how LYRA's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for LYRA and 80,000+ other tickers.
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under…
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the "SEC") on Monday, April 20, 2026, to remove its common stock from listing and registration on The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed, trading in the Company's common stock was suspended by Nasdaq on March 17, 2026. Although Nasdaq has indicated it intends to file its own Form 25 after all internal procedural periods have run, it has not yet done so. The Company is therefore voluntarily filing Form 25 in order to proceed with deregistration. The Company's common stock is currently quoted on the Pink Limited Market. This press release is being issued in compliance with Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company's lead product candidate for the treatment of chronic rhinosinusitis (CRS).
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 0.3% on Friday. The stock traded as high as $3.70 and last traded at $3.59. Approximately 32,339 shares changed hands during trading, a decline of 4% from the average daily volume of 33,546 shares. The stock had previously closed at $3.58. Analysts
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 4.5% on Wednesday. The stock traded as high as $4.32 and last traded at $4.19. Approximately 48,758 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 94,587 shares. The stock had previously closed at $4.01.